FIELD: organic chemistry, medicine, biochemistry, pharmacy.
SUBSTANCE: invention describes novel derivatives of 1,2,4-triazole of the general formula (I): 
wherein A and b can be taken separately or in common being when they are taken separately then A means (C1-C6)-alkyl or phenyl, and B means (C1-C6)-alkyl; A and B taken in common mean (C2-C5)-alkanediyl, and they form with C-atoms 3-6-membered cycle optionally substituted with (C1-C4)-alkylene, oxo, ethylenedioxy group, (C1-C4)-alkyl, 1-2 halogen atoms, (C1-C3)-alkoxy-(C1-C3)-alkoxy or hydroxy group; each R1 means independently hydrogen atom, -OH, halogen atom, (C3-C6)-cycloalkyl, (C1-C6)-alkyl optionally substituted with 1-3 halogen atoms; or two R1 groups near adjacent carbon atoms form 6-membered aryl cycle; R2 and R3 can be taken in common or separately, and when they are taken in common then they represent (C3-C8)-alkanediyl that forms condensed 5-10-membered nonaromatic cycle; when R2 and R3 are taken separately then R2 means (C1-C6)-alkyl possibly substituted with 1-3 halogen atoms or cyclopropyl, and R3 means cyclopropyl possibly substituted with (C1-C4)-alkyl, naphthyl, phenyl possibly substituted with halogen atom, -OH, (C1-C6)-alkyl wherein indicated (C1-C6)-alkyl is optionally substituted with 1-3 halogen atoms, -O-(C1-C6)-alkyl wherein indicated -O-(C1-C6)-alkyl is optionally substituted with 1-3 halogen atoms, phenyl or benzyloxy group, dihydrobenzofuranyl, benzothiadiazolyl or benzoimidazolyl possibly substituted with (C1-C6)-alkyl, their pharmaceutically acceptable salts or solvates, and pharmaceutical composition based on thereof. Proposed compounds are inhibitor of 11β-hydroxysteroid dehydrogenase I, and can be used in medicine in treatment of diabetes mellitus, obesity and dyslipidemia.
EFFECT: valuable medicinal and biochemical properties of compounds and pharmaceutical composition.
19 cl, 17 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF 1,2,4-TRIAZOLO[4,3-B]PYRIDO[3,2-D]-PYRIDAZINE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITION OF PHOSPHODIESTERASE IV ACTIVITY | 1998 |
|
RU2202552C2 |
| 5-ARYL-1H-1,2,4-TRIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 2000 |
|
RU2249588C2 |
| PYRIDAZINE DERIVATIVE INHIBITOR, METHOD OF ITS PREPARATION AND ITS USE | 2020 |
|
RU2807611C2 |
| NOVEL HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2769507C1 |
| AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR TREATING OR PREVENTING DIABETES | 2010 |
|
RU2550508C2 |
| SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRIDINES, DEMONSTRATING PROPERTIES OF ANTAGONISTS OF ADENOSINE A2A RECEPTORS, AND THEIR APPLICATION | 2013 |
|
RU2534804C1 |
| TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1 | 2003 |
|
RU2360910C2 |
| OXAZINMONOACYLGLYCERIN LIPASE (MAGL) INHIBITORS | 2019 |
|
RU2794334C2 |
| METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | 2020 |
|
RU2820673C2 |
| TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2677697C1 |
